interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Pirtobrutinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Pirtobrutinib, and who makes it?

Pirtobrutinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Pirtobrutinib1 dosage-form group in the Orange Book
0generic makers listed
  1. Pirtobrutinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Jaypirca. No generic is listed as marketed.

20202025203020352040204501brand 2023data datePatent 10918622 listed to expire 16 December 2036Patent 10695323 listed to expire 16 December 2036Patent 10464905 listed to expire 16 December 2036Patent 12220401 listed to expire 16 December 2036Patent 10342780 listed to expire 16 December 2036Patent 12268666 listed to expire 29 July 2039Patent 12109193 listed to expire 14 September 2041Exclusivity NCE to 27 January 2028Exclusivity I-981 to 2 December 2028Exclusivity ODE-424 to 27 January 2030Exclusivity ODE-451 to 1 December 2030Exclusivity ODE-518 to 3 December 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 January 2028Exclusivity NCE Jaypirca
  • 2 December 2028Exclusivity I-981 Jaypirca
  • 27 January 2030Exclusivity ODE-424 Jaypirca
  • 1 December 2030Exclusivity ODE-451 Jaypirca
  • 3 December 2032Exclusivity ODE-518 Jaypirca
  • 16 December 2036Patent 10918622
  • 16 December 2036Patent 10695323 drug substance
  • 16 December 2036Patent 10464905
  • 16 December 2036Patent 12220401 drug substance
  • 16 December 2036Patent 10342780 drug substance
  • 29 July 2039Patent 12268666 drug product
  • 14 September 2041Patent 12109193 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.